Desvenlafaxine vs. Placebo Treatment of Chronic Depression
|ClinicalTrials.gov Identifier: NCT01537068|
Recruitment Status : Completed
First Posted : February 22, 2012
Results First Posted : September 11, 2017
Last Update Posted : September 11, 2017
The investigators are studying a new antidepressant medicine, desvenlafaxine, for the treatment of people with chronic depression. Desvenlafaxine (trade name Pristiq) has been approved by the FDA for the treatment of major depression.
The investigators are testing whether this medicine is also effective for adults with a type of chronic depression that is less severe than major depression. This condition is also known as dysthymic disorder or dysthymia. Chronic depression, lasting two or more years, often causes significant suffering and impairment.
In addition, the investigators are using MRI imaging, which uses magnetic signals to make pictures of the brain's structure and also of its functioning. The purpose of MRI imaging in this study is to see whether chronic depression is associated with differences in brain structure or functioning, and whether such differences change after medication or placebo treatment. To test this MRI scans are done at the start of the study and after 12 weeks of medication or placebo treatment. Getting MRI imaging will be an option for participants in this study but is not required.
This study involves a 6 to 12 week double-blind period during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the double blind phase, all subjects can be treated for 12 weeks with an FDA-approved antidepressant medication.
Assessments (of depressive symptoms, social functioning, and personality) will be done by study staff and by patients before the study starts, at each study visit for the first 12 weeks, and again after 24 weeks in the study.
|Condition or disease||Intervention/treatment||Phase|
|Dysthymic Disorder Dysthymia Chronic Depressive Disorder||Drug: Desvenlafaxine Drug: Placebo||Phase 4|
The investigators wish to study acute efficacy for 12 weeks on a double blind basis and continued response after open-label treatment at week 24 follow-up. It is important to establish the acute (12 week) efficacy of desvenlafaxine in non-major chronic depression. Also, given that non-major chronic depression is by definition chronic, it is important to demonstrate that benefit persists at follow-up assessment (24 weeks); this is clinically important in trying to alleviate the significant psychosocial morbidity associated with this disorder.
The investigators believe this study will have significant value in the treatment of patients with non-major chronic depression, and will add significantly to what remains an extremely small scientific literature.
The investigators would also like to study the effects of desvenlafaxine on brain structure and function. Learning that a medication reduces symptoms does not teach us how the medication achieves this outcome. Participants in this study can have the opportunity to participate in MRI scanning that will help to understand the mechanisms by with desvenlafaxine is effective. MRI scans are done prior to starting the clinical trial and then again after completing the double blind clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||59 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression|
|Actual Study Start Date :||February 2012|
|Primary Completion Date :||August 2016|
|Study Completion Date :||December 2016|
Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
Desvenlafaxine oral dose ranging from 50 to 100 mg/day
Other Name: Pristiq
Placebo Comparator: Placebo
Matching placebo pills
Other Name: Inactive comparator
- Hamilton Rating Scale for Depression (HDRS24) [ Time Frame: Baseline ]HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression
- Hamilton Rating Scale for Depression (HDRS24) [ Time Frame: Week 12 ]HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression
- Response Rate [ Time Frame: 12 weeks ]Assessment of overall improvement: based on HDRS and Clinical Global Improvement Scale Response Rate is defined as 50% improvement of Hamd24 summary scores from baseline.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01537068
|United States, New York|
|New York State Psychiatric Institute/3 Columbus Circle Midtown|
|New York, New York, United States, 10019|
|Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry|
|New York, New York, United States, 10032|
|Principal Investigator:||David J Hellerstein, MD||New York State Psychiatric Institute, Columbia University Department of Psychiatry|